p14ARF expression in invasive breast cancers and ductal carcinoma in situ- relationships to p53 and Hdm2

Breast Cancer Research

Volumn 6, Issue 5, 2004, Pages

  Vestey, S B ^a   Sen, C ^b   Calder, C J ^b   Perks, C M ^a   Pignatelli, M ^b   Winters, Z E ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

ARF protein; Ductal carcinoma in situ; Hdm2; HER 2; Immunohistochemistry

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; PROTEIN MDM2; TRANSCRIPTION FACTOR TWIST; UBIQUITIN PROTEIN LIGASE E3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN P14ARF; PROTEIN P53;

ADULT; ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; NEGATIVE FEEDBACK; OVERALL SURVIVAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STABILITY; TUMOR INVASION; TUMOR VOLUME; AGED; BREAST TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4644280243     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr912     Document Type: Article

References (62)

1. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR: The p53 network. J Biol Chem. 1998, 273: 1-4. 10.1074/jbc.273.1.1.
2. Sharpless NE, DePinho RA: The INK4a/ARF locus and its two gene products. Curr Opin Genet Dev. 1999, 9: 22-30. 10.1016/S0959-437X(99)80004-5.
3. Vousden KH, Vande Woude GF: The ins and outs of p53. Nat Cell Biol. 2000, 2: E178-E180. 10.1038/35036427.
4. Laín S, Xirodimas D, Lane DP: Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function. Exp Cell Res. 1999, 253: 315-324. 10.1006/excr.1999.4672.
5. Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA. 1992, 89: 7262-7266.
6. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ: Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by human immunodeficiency virus rev protein. EMBO J. 1998, 17: 554-564. 10.1093/emboj/17.2.554.
7. Tao W, Levine AJ: Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA. 1999, 96: 3077-3080. 10.1073/pnas.96.6.3077.
8. Lu W, Pochampally R, Chen L, Traidej M, Wang Y, Chen J: Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene. 2000, 19: 232-240. 10.1038/sj.onc.1203262.
9. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 1999, 18: 22-27. 10.1093/emboj/18.1.22.
10. Sherr CJ, Weber JD: The ARF/p53 pathway. Curr Opin Genet Dev. 2000, 10: 94-99. 10.1016/S0959-437X(99)00038-6.
11. Sherr CJ: Tumor surveillance via the ARF-p53 pathway. Genes Dev. 1998, 12: 2984-2991.
12. Lloyd AC: p53 only ARF the story. Nat Cell Biol. 2000, 2: E48-E50. 10.1038/35004078.
13. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G: The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998, 17: 5001-5014. 10.1093/emboj/17.17.5001.
14. Sherr CJ: The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol. 2001, 2: 731-737. 10.1038/35096061.
15. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumour suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995, 83: 993-100. 10.1016/0092-8674(95)90214-7.
16. Zindy F, Eischen CM, Randle D, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF: Myc signalling via the ARF tumour suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998, 12: 2424-2433.
17. Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL, Roussel MF, Sherr CJ: Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci USA. 2003, 100: 15930-15935. 10.1073/pnas.2536808100.
18. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997, 91: 649-659. 10.1016/S0092-8674(00)80452-3.
19. Silva J, Silva JM, Dominguez G, Garcia JM, Cantos B, Rodriguez R, Larrondo FJ, Provencio M, Espana P, Bonilla F: Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Pathol. 2003, 199: 289-297. 10.1002/path.1297.
20. Hui R, Macmillan RD, Kenny FS, Musgrove EA, Blamey RW, Nicholson RI, Robertson JFR, Sutherland RL: INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res. 2000, 6: 2777-2787.
21. ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res. 2001, 61: 2816-2821.
22. Khan SH, Moritsugu J, Wahl GM: Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc Natl Acad Sci USA. 2000, 97: 3266-3271. 10.1073/pnas.050560997.
23. Eymin B, Leduc C, Coll JL, Brambilla E, Gazzeri S: p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene. 2003, 22: 1822-1835. 10.1038/sj.onc.1206303.
24. ARF in homeostatic tissues. Mol Cell Biol. 2004, 24: 186-191. 10.1128/MCB.24.1.186-191.2004.
25. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G: The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998, 17: 5001-5014. 10.1093/emboj/17.17.5001.
26. Rizos H, Darmanian AP, Mann GJ, Kefford RF: Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Oncogene. 2000, 19: 2978-2985. 10.1038/sj.onc.1203629.
27. ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol. 2001, 3: 445-452. 10.1038/35074506.
28. Xirodimas D, Saville MK, Edling C, Lane DP, Laín S: Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene. 2001, 20: 4972-4983. 10.1038/sj.onc.1204656.
29. ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene. 2000, 19: 2312-2323. 10.1038/sj.onc.1203593.
30. ARF nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. Blood. 2002, 99: 1411-1418. 10.1182/blood.V99.4.1411.
31. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, Hannon GJ: Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999, 13: 2207-2217. 10.1101/gad.13.17.2207.
32. Jacobs JJL, Scheijen B, Voncken J-W, Kieboom K, Berns A, van Lohuizen M: Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via IK4a/ARF. Genes Dev. 1999, 13: 2678-2690. 10.1101/gad.13.20.2678.
33. Sugihara T, Kaul SC, Kato J-y, Reddel RR, Nomura H, Wadhwa R: Pex19p dampens the p19ARF-p53-p21WAF1 tumor suppressor pathway. J Biol Chem. 2001, 276: 18649-18652. 10.1074/jbc.C100011200.
34. Vonlanthen S, Heighway J, Tschan MP, Borner MM, Altermatt HJ, Kappeler A, Tobler A, Fey MF, Thatcher N, Yarbrough WG, Betticher DC: Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene. 1998, 17: 2779-2785. 10.1038/sj.onc.1202501.
35. Sano T, Hikino T, Xue Q, Saito T, Kashiwabara K, Oyama T, Nakajima T: Immunohistochemical inactivation of p14ARF concomitant with MDM2 overexpression inversely correlates with p53 overexpression in oral squamous cell carcinoma. Pathology Int. 2000, 50: 709-716. 10.1046/j.1440-1827.2000.01109.x.
36. Geradts J, Wilentz RE, Roberts H: Immunohistochemical detection of the alternate INK4a-encoded tumor suppressor protein p14ARF in archival human cancers and cell lines using commercial antibodies: correlation with p16INK4a expression. Mod Pathol. 2001, 14: 1162-1168. 10.1038/modpathol.3880452.
37. INK4a expression. Mod Pathol. 2002, 15: 1106-1107. 10.1097/01.MP.0000030090.45666.DB. (letter)
38. Silva J, Domínguez G, Silva JM, García JM, Gallego I, Corbacho C, Provencio M, Espana P, Bonilla F: Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene. 2001, 20: 4586-4590. 10.1038/sj.onc.1204617.
39. Domínguez G, Silva J, Silva JM, Garcia JM, Larrondo FJ, Vargas J, Sanfrutos L, Provencio M, Espana P, Bonilla F: Different expression of P14ARF defines two groups of breast carcinomas in terms of TP73 expression and TP53 mutational status. Genes Chromosomes Cancer. 2001, 31: 99-106. 10.1002/gcc.1123.abs.
40. Galea MH, Blamey RW, Elston CW, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992, 22: 207-219.
41. Silverstein MJ, Poller DN, Waisman JR: Prognostic classification of breast ductal carcinoma in situ. Lancet. 1995, 345: 1154-1157. 10.1016/S0140-6736(95)90982-6.
42. National Breast Screening Programme: Pathology Reporting in Breast Cancer Screening. 1995, Sheffield, UK: NHSBSP Publications, 2
43. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410.
44. Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K, Walker R: Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol. 2000, 53: 634-635. 10.1136/jcp.53.8.634.
45. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ: COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer. 2004, 90: 423-429. 10.1038/sj.bjc.6601534.
46. Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ: Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumours: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol. 2002, 118: 408-417. 10.1309/97WN-W6UX-XJWT-02H2.
47. Marchetti A, Buttitta F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, Doglioni C, Bevilacqua G, Barbareschi M: mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol. 1995, 175: 31-38.
48. O'Neill M, Campbell SJ, Save V, Thompson AM, Hall PA: An immunochemical analysis of mdm2 expression in human breast cancer and the identification of a growth-regulated cross-reacting species p170. J Pathol. 1998, 186: 254-261. 10.1002/(SICI)1096-9896(1998110)186:3<254::AID-PATH185>3.3.CO;2-L.
49. Sjögren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996, 88: 173-182.
50. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res. 1989, 49: 1052-1056.
51. WAF1/CIP1 in breast cancer: association with prognosis. Eur J Cancer. 2001, 37: 2405-2412. 10.1016/S0959-8049(01)00327-6.
52. WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res. 2003, 5: R242-R249. 10.1186/bcr654.
53. Kuukasjarvi T, Tanner M, Pennanen S, Karhu R, Kallioniemi O-P, Isola J: Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol. 1997, 150: 1465-1471.
54. Roylance R, Gorman P, Harris W, Liebmann R, Barnes D, Hanby A, Sheer D: Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res. 1999, 59: 1433-1436.
55. INK4a methylation and p53 mutational status. Cancer Res. 2000, 60: 129-133.
56. Freedman DA, Wu L, Levine AJ: Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999, 55: 96-107. 10.1007/s000180050273.
57. Marchetti A, Buttitta F, Girlando S, Palma PD, Pellegrini S, Fina P, Doglioni C, Bevilacqua G, Barbareschi M: Mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol. 1995, 175: 31-38.
58. Bueso-Ramos CE, Manshouri T, Haidar MA, Yang Y, McCown P, Ordonez N, Glassman A, Sneige N, Albitar M: Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat. 1996, 37: 179-188.
59. Lohrum MAE, Ashcroft M, Kubbutat MHG, Vousden KH: Identification of a cryptic nucleolar-localization signal in MDM2. Nat Cell Biol. 2000, 2: 179-181. 10.1038/35004057.
60. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung M-C: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001, 3: 973-982. 10.1038/ncb1101-973.
61. D'Amico M, Wu K, Di Vizio D, Reutens AT, Stahl M, Fu M, Albanese C, Russell RG, Muller WJ, White M, Negassa A, Lee HW, DePinho RA, Pestell RG: The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. Cancer Res. 2003, 63: 3395-3402.
62. Stenmark-Askmalm M, Stal O, Sullivan S, Ferraud L, Sun XF, Carstensen J, Nordenskjold B: Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer. 1994, 30A: 175-180. 10.1016/0959-8049(94)90082-5.